St Vincent adds BRCA2 to testing service
This article was originally published in Clinica
Executive Summary
St Vincent Medical Center's Los Angeles Oncologic Institute has extended its breast cancer gene diagnosis service to include the recently discovered breast and ovarian cancer gene, BRCA2. The unit, headed by Dr Ellen Knell, has been testing for BRCA1 mutations for six months. The service is available to women with a family history of breast and ovarian cancer and at least one living affected relative, and Ashkenazi Jewish women, who are at very high risk of inherited breast cancer. Affected relatives are needed because not all mutations change the function of the gene.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.